• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Report: Drugmakers may have ducked $1.3B in Medicaid rebates

December 21, 2017 By Sarah Faulkner

CMSWithout calling out any drug companies by name, the U.S. Dept. of Health and Human Services’ Office of Inspector General revealed this week that 10 potentially misclassified drugs may have resulted in $1.3 billion in lost rebates to Medicaid between 2012 and 2016.

The issue of ducking rebates came to the public’s attention earlier this year when Mylan (NSDQ:MYL) reached a $465 million settlement with the Dept. of Justice to resolve claims that the company misclassified its EpiPen auto-injectors as generic rather than branded to avoid paying a higher rebate.

The HHS study compared classifications for drugs in the Medicaid rebate program as reported by drug manufacturers with data from the FDA and found that 98% of the products were “classified appropriately,” according to RAPS.

However, the report revealed that 885 products out of the 30,000 drugs in the Medicaid rebate program were misclassified in 2016 and data were missing for more than 600 other drugs. The report also showed that there was no Medicaid reimbursement for one-third of the potentially misclassified drugs last year.

Although the report didn’t mention companies by name, it did note that just four manufacturers were responsible for more than half of the potential misclassifications.

The Office of Inspector General’s office recommended that the Centers for Medicare and Medicaid Services contact the manufacturers linked to the potentially misclassified products and identify a way to urge companies to update wrongly-classified drugs.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Centers for Medicare and Medicaid Services (CMS)

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS